Squarepoint Ops LLC Cuts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Squarepoint Ops LLC lessened its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 38.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,616 shares of the company's stock after selling 31,613 shares during the period. Squarepoint Ops LLC owned about 0.05% of Dyne Therapeutics worth $1,216,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its position in Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after purchasing an additional 698 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after buying an additional 721 shares in the last quarter. KBC Group NV lifted its stake in Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after buying an additional 978 shares in the last quarter. E Fund Management Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after acquiring an additional 1,249 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 11.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock worth $508,000 after buying an additional 2,265 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on DYN. Piper Sandler decreased their price target on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Evercore ISI started coverage on Dyne Therapeutics in a research note on Thursday, May 29th. They issued an "outperform" rating and a $46.00 target price for the company. Scotiabank began coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. HC Wainwright decreased their price target on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, BMO Capital Markets initiated coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $45.54.

Dyne Therapeutics Price Performance

DYN traded up $0.14 during trading on Wednesday, hitting $13.41. The stock had a trading volume of 1,975,361 shares, compared to its average volume of 1,639,399. The company has a 50 day moving average price of $10.40 and a 200-day moving average price of $15.96. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $47.45. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -3.77 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.